electroCore, Inc.
NASDAQ:ECOR

Watchlist Manager
electroCore, Inc. Logo
electroCore, Inc.
NASDAQ:ECOR
Watchlist
Price: 6.81 USD -4.89% Market Closed
Market Cap: 44.6m USD

electroCore, Inc.
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

electroCore, Inc.
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
electroCore, Inc.
NASDAQ:ECOR
Accounts Receivables
$1.4m
CAGR 3-Years
51%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Accounts Receivables
$2.6B
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
10%
Boston Scientific Corp
NYSE:BSX
Accounts Receivables
$2.5B
CAGR 3-Years
12%
CAGR 5-Years
6%
CAGR 10-Years
8%
Stryker Corp
NYSE:SYK
Accounts Receivables
$4B
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
10%
Abbott Laboratories
NYSE:ABT
Accounts Receivables
$6.9B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
7%
Intuitive Surgical Inc
NASDAQ:ISRG
Accounts Receivables
$1.2B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
15%

electroCore, Inc.
Glance View

Market Cap
45.3m USD
Industry
Health Care

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).

ECOR Intrinsic Value
20.66 USD
Undervaluation 67%
Intrinsic Value
Price

See Also

What is electroCore, Inc.'s Accounts Receivables?
Accounts Receivables
1.4m USD

Based on the financial report for Dec 31, 2024, electroCore, Inc.'s Accounts Receivables amounts to 1.4m USD.

What is electroCore, Inc.'s Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
22%

Over the last year, the Accounts Receivables growth was 91%. The average annual Accounts Receivables growth rates for electroCore, Inc. have been 51% over the past three years , 22% over the past five years .

Back to Top